The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur
Open accessAbstract
BACKGROUND: A number of recent case reports and series have identified a subgroup of atypical fractures of the femoral shaft associated with bisphosphonate use. A population-based study did not support this association. Such a relationship has not been examined in randomized trials. METHODS: We performed secondary analyses using the results of three large, randomized bisphosphonate trials: the Fracture Intervention Trial (FIT), the FIT Long-Term Extension (FLEX) trial, and the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Pivotal Fracture Trial (PFT). We reviewed fracture records and radiographs (when available) from all hip and femur fractures to identify those below the lesser trochanter and above the distal metaphyseal flare (subtrochanteric and diaphyseal femur fractures) and to assess atypical features. We calculated the relative hazards for subtrochanteric and diaphyseal fractures for each study. RESULTS: We reviewed 284 records for hip or femur fractures among 14,195 women in these trials. A total of 12 fractures in 10 patients were classified as occurring in the subtrochanteric or diaphyseal femur, a combined rate of 2.3 per 10,000 patient-years. As compared with placebo, the relative hazard was 1.03 (95% confidence interval [CI], 0.06 to 16.46) for alendronate use in the FIT trial, 1.50 (95% CI, 0.25 to 9.00) for zoledronic acid use in the HORIZON-PFT trial, and 1.33 (95% CI, 0.12 to 14.67) for continued alendronate use in the FLEX trial. Although increases in risk were not significant, confidence intervals were wide. CONCLUSIONS: The occurrence of fracture of the subtrochanteric or diaphyseal femur was very rare, even among women who had been treated with bisphosphonates for as long as 10 years. There was no significant increase in risk associated with bisphosphonate use, but the study was underpowered for definitive conclusions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Self-citationOnce-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black, D. M., Delmas, P. D., Eastell, R., Reid, I. R., Boonen, S., Cauley, J. A., Cosman, F., Lakatos, P., Leung, P. C., Man, Z., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067312 · Cited by 2,986
Self-citationSeverely Suppressed Bone Turnover: A Potential Complication of Alendronate Therapy
Odvina, C. V., Zerwekh, J. E., Rao, D. S., Maalouf, N., Gottschalk, F. A., & Pak, C. Y. C. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0952 · Cited by 1,432
Black, D. M., Schwartz, A. V., Ensrud, K. E., Cauley, J. A., Levis, S., Quandt, S. A., Satterfield, S., Wallace, R. B., Bauer, D. C., Palermo, L., et al. (2006) · JAMA · doi:10.1001/jama.296.24.2927 · Cited by 1,407
Self-citationFracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial
Black, D. M., Thompson, D. E., Bauer, D. C., Ensrud, K., Musliner, T., Hochberg, M. C., Nevitt, M. C., Suryawanshi, S., & Cummings, S. R. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6953 · Cited by 982
Self-citationLow-Energy Femoral Shaft Fractures Associated With Alendronate Use
Neviaser, A. S., Lane, J. M., Lenart, B. A., Edobor-Osula, F., & Lorich, D. G. (2008) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0b013e318172841c · Cited by 526
Subtrochanteric insufficiency fractures in patients on alendronate therapy: A CAUTION
Goh, S.-K., Yang, K. Y., Koh, J. S. B., Wong, M. K., Chua, S. Y., Chua, D. T. C., & Howe, T. S. (2007) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.89b3.18146 · Cited by 513
Atypical Fractures of the Femoral Diaphysis in Postmenopausal Women Taking Alendronate
Lenart, B. A., Lorich, D. G., & Lane, J. M. (2008) · New England Journal of Medicine · doi:10.1056/nejmc0707493 · Cited by 498
Kwek, E. B. K., Goh, S. K., Koh, J. S. B., Png, M. A., & Howe, T. S. (2008) · Injury · doi:10.1016/j.injury.2007.08.036 · Cited by 445
Cited by
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Self-citationBlack, D. M., & Rosen, C. J. (2016) · New England Journal of Medicine · doi:10.1056/nejmcp1513724 · Cited by 1,712
Self-citationShane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
Self-citationBlack, D. M., Reid, I. R., Boonen, S., Bucci-Rechtweg, C., Cauley, J. A., Cosman, F., Cummings, S. R., Hue, T. F., Lippuner, K., Lakatos, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1494 · Cited by 700
Self-citationBisphosphonate Use and Atypical Fractures of the Femoral Shaft
Schilcher, J., Michaëlsson, K., & Aspenberg, P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010650 · Cited by 695
Glucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 694
Use of bone turnover markers in postmenopausal osteoporosis
Eastell, R., & Szulc, P. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30184-5 · Cited by 594
Self-citationComplex Regional Pain Syndrome: Practical Diagnostic and Treatment Guidelines, 4th Edition
Harden, R. N., Oaklander, A. L., Burton, A. W., Perez, R. S. G. M., Richardson, K., Swan, M., Barthel, J., Costa, B., Graciosa, J. R., & Bruehl, S. (2013) · Pain Medicine · doi:10.1111/pme.12033 · Cited by 534
Osteoporosis Imaging: State of the Art and Advanced Imaging
Link, T. M. (2012) · Radiology · doi:10.1148/radiol.12110462 · Cited by 453
Bisphosphonate Use and the Risk of Subtrochanteric or Femoral Shaft Fractures in Older Women
Park-Wyllie, L. Y. (2011) · JAMA · doi:10.1001/jama.2011.190 · Cited by 442
Incidence of atypical nontraumatic diaphyseal fractures of the femur
Dell, R. M., Adams, A. L., Greene, D. F., Funahashi, T. T., Silverman, S. L., Eisemon, E. O., Zhou, H., Burchette, R. J., & Ott, S. M. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1719 · Cited by 441
Bone Disease in HIV Infection: A Practical Review and Recommendations for HIV Care Providers
McComsey, G. A., Tebas, P., Shane, E., Yin, M. T., Overton, E. T., Huang, J. S., Aldrovandi, G. M., Cardoso, S. W., Santana, J. L., & Brown, T. T. (2010) · Clinical Infectious Diseases · doi:10.1086/656412 · Cited by 396
Glucocorticoid-Induced Osteoporosis and Osteonecrosis
Weinstein, R. S. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.004 · Cited by 364
A Crisis in the Treatment of Osteoporosis
Khosla, S., & Shane, E. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2888 · Cited by 319
Atypical fractures of the femur and bisphosphonate therapy
Giusti, A., Hamdy, N. A. T., & Papapoulos, S. E. (2010) · Bone · doi:10.1016/j.bone.2010.05.019 · Cited by 295
Benefits and risks of bisphosphonate therapy for osteoporosis
Khosla, S., Bilezikian, J. P., Dempster, D. W., Lewiecki, E. M., Miller, P. D., Neer, R. M., Recker, R. R., Shane, E., Shoback, D., & Potts, J. T. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1027 · Cited by 290
“A secondary analysis of all hip and femur fractures that occurred in three large randomized clinical trials of alendronate and zoledronate did not find an increased risk of subtrochanteric or femoral shaft fractures, but given that fractures in this location account for only 5 to 10% of all proximal femur fractures, t…”
BackgroundPrespecified Falsification End Points: Can They Validate True Observational Associations?
Prasad, V., & Jena, A. B. (2013) · JAMA · doi:10.1001/jama.2012.96867 · Cited by 283
Ayers, C., Kansagara, D., Lazur, B., Fu, R., Kwon, A., & Harrod, C. (2023) · Annals of Internal Medicine · doi:10.7326/m22-0684 · Cited by 282
Gedmintas, L., Solomon, D. H., & Kim, S. C. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1893 · Cited by 256
Crandall, C. J., Newberry, S. J., Diamant, A., Lim, Y.-W., Gellad, W. F., Booth, M. J., Motala, A., & Shekelle, P. G. (2014) · Annals of Internal Medicine · doi:10.7326/m14-0317 · Cited by 254
Lloyd, A. A., Gludovatz, B., Riedel, C., Luengo, E. A., Saiyed, R., Marty, E., Lorich, D. G., Lane, J. M., Ritchie, R. O., Busse, B., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704460114 · Cited by 158
Paradoxical side effects of bisphosphonates on the skeleton: What do we know and what can we do?
Vargas‐Franco, J. W., Castaneda, B., Rédiní, F., Gómez, D. F., Heymann, D., & Lézot, F. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26465 · Cited by 64
Mansjur, K. Q., Kuroda, S., Izawa, T., Maeda, Y., Sato, M., Watanabe, K., Horiuchi, S., & Tanaka, E. (2016) · Annals of Biomedical Engineering · doi:10.1007/s10439-015-1533-y · Cited by 27
Metadata
- Authors
- Black, D. M., Kelly, M. P., Genant, H. K., Palermo, L., Eastell, R., Bucci-Rechtweg, C., Cauley, J., Leung, P. C., Boonen, S., Santora, A., de Papp, A., & Bauer, D. C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-05-13
- Volume
- 362
- Issue
- 19
- Pages
- 1761-1771
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151825217
- Cited by
- 512
- References
- 27
- FWCI
- 84.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.